Lilly and Alcon Eye Success with Treatment for Diabetic Retinopathy
By Business Review Editor
PharmaDeals Review: Vol 2006 Issue 75 (Table of Contents)
Published: 6 Sep-2006
DOI: 10.3833/pdr.v2006i75.465 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Eli Lilly and Alcon entered into agreement to co-promote Alcon’s ruboxistaurin mesylate (Arxxant™) for treating moderate-to-severe, severe non-proliferative diabetic retinopathy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
Login Problems
RSS